TNF and rheumatoid arthritis: According to our results, adalimumab was the most commonly prescribed TNF alpha inhibitor among 33.3% (n = 17 of the RA participants, followed by etanercept and golimumab, representing 27.45% (n = 14) and 15.68% (n = 8, respectively.